Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

287.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Planned CEO Leadership Transition
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.